Previous 10 | Next 10 |
Mersana Therapeutics, Inc. (MRSN) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin ...
Mersana Therapeutics press release ( NASDAQ: MRSN ): Q3 GAAP EPS of -$0.61 misses by $0.60 . Revenue of $5.57M (vs. $0.01M) misses by $51.21M . Cash, cash equivalents and marketable securities as of September 30, 2022, were $290.1M, compared to cash and cash eq...
Completed enrollment in UPLIFT clinical trial; topline data expected mid-2023; potential Biologics License Application (BLA) submission anticipated by the end of 2023 Initiated patient enrollment and dosing in Phase 1 clinical trial of XMT-1660 Strengthened balance sheet...
Mersana Therapeutics ( NASDAQ: MRSN ) is scheduled to announce Q3 earnings results on Sunday, November 6th, before market open. The consensus EPS Estimate is $0.06 (+109.5% Y/Y) and the consensus Revenue Estimate is $56.78M (-70.4% Y/Y). Over the last 3 months, EPS est...
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Topline data from UPLIFT expected in mid-2023 Targeting potential Biologics License Application (BLA) submission by the end of 2023 CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical compa...
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS : an educational platform for healthcare providers that will address clinically impactful topics in g...
Clinical-stage biotech Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) added ~8% in the pre-market trading on the announcement that the FDA issued its Fast Track designation for the company’s antibody-drug conjugate XMT-1660 as a treatment for adults with triple-negativ...
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...